CLOs on the Move

Wondr Health

www.wondrhealth.com

 
Wondr Health™ is a digital behavioral change program focused on weight management that helps participants improve their physical and mental wellbeing through simple, interactive, and clinically-proven skills and tools. By treating the root cause of obesity through behavioral science, Wondr reduces risk factors to prevent chronic diseases like diabetes and hypertension, helps enhance employee productivity and engagement, decreases claims costs, and improves overall wellbeing. Wondr Health`s team of renowned doctors and scientists teaches practical, data-backed skills that empower participants to stress less, sleep better, and feel better. The highly personalized program has helped hundreds of thousands of people by teaching ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.wondrhealth.com
  • 12712 Park Central Drive Suite 100
    Dallas, TX USA 75251
  • Phone: 855.999.7549

Executives

Name Title Contact Details

Similar Companies

Houck Limited

Houck Limited is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quality Health

Quality Health is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bunnell

Bunnell is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Texas Visiting Nurse Service

Texas Visiting Nurse Service is a Harlingen, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.